Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years. [Read more…]
RoosterBio Commercializes Industry’s First cGMP Human MSC Banks For Widespread Manufacturing
RoosterBio Launches Only Commercially-Available Working Cell Banks (WCBs) for Large-Scale hMSC Production
Frederick, MD, USA. January 24, 2018 – RoosterBio Inc., a leading manufacturer of adult, allogeneic human mesenchymal stem/stromal cells (hMSCs) and paired bioprocess media systems, continues to deliver on its mission to de-bottleneck and accelerate the Regenerative Medicine Industry by launching the only commercially-available working cell banks (WCBs) for large scale hMSC production. [Read more…]
Exciting Early Results in Cynata’s UK Trial of iPSC-Derived MSC Therapeutic Product
Patients in Cohort A Respond Well, 1st Patient in Cohort B Dosed in Cynata’s CYP-001 Trial
Australian stem cell company, Cynata Therapeutics has released exciting early results from its ongoing clinical trial in the UK utilizing an iPS cell-derived mesenchymal stem cell (MSC) therapeutic product. [Read more…]
Pluristem’s PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study
- PLX cells exhibit anti-proliferative effect on a wide range of human cancer cell types
- Pre-clinical study results show statistically significant reduction in tumor size as well as complete tumor remission in 30% of treated recipients
HAIFA, Israel, Jan. 12, 2018 — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced the publication of a peer-reviewed article in the journal Scientific Reports, from the publisher of Nature, titled, “Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF‑α and IFN‑γ Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft Models.”
The article is based on studies which examined the effect of PLX cells that had been induced with tumor necrosis factor alpha (TNF-α) and interferon-gamma (IFN-γ), on the proliferation of over 50 lines of human cancerous cells. The induction of the cells was carried out by adjusting their manufacturing process in order to transiently alter their secretion profile. [Read more…]
The Making of a Stem Cell Super-Ecosystem with Bernard Siegel
I am honored to share this interview with Bernard Siegel, Executive Director of the Regenerative Medicine Foundation (RMF), a global network of stakeholders that fosters collaboration across the industry. Bernard is also the Founder and Chair of the World Stem Cell Summit (WSCS), my favorite stem cell industry event of the year, because it attracts a global super-ecosystem of stem cell industry stakeholders.
In this interview, we explore his background, changes within the regenerative medicine sector, the importance of industry collaboration, and future directions for stem cell medicine. [Read more…]
- « Previous Page
- 1
- …
- 118
- 119
- 120
- 121
- 122
- …
- 201
- Next Page »